Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B (TAF-PPT)

Safety and Efficacy of Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B (TAF-PPT): A Multicentre, Prospective, Open-label, Randomized Controlled Trial

To investigate the safety and efficacy of tenofovir alafenamide (orally 25 mg per day) treated in inactive chronic hepatitis B virus (HBV)-infected pregnant women with high viral load from the late pregnancy until the delivery date or postpartum 1 month.

Study Overview

• Status: Not yet recruiting
• Conditions: Chronic Hepatitis B; Efficacy; Safety; Hepatitis B Virus; Mother-to-Child Transmission; Tenofovir Alafenamide Fumarate
• Intervention / Treatment: Drug: Tenofovir Alafenamide fumarate 25mg Oral Tablet

Detailed Description

The investigators intend to include 240 inactive chronic hepatitis B virus (HBV)-infected pregnant women who have an HBV DNA level higher than 200,000 IU per milliliter. Participants will be randomly assigned, in a 1:1 ratio, to receive tenofovir alafenamide (orally 25 mg per day) from the late pregnancy until the delivery date or postpartum 1 month. All the infants will receive standard immunoprophylaxis (100 IU of hepatitis B immunoglobulin and 10 μg of hepatitis B vaccine within 12 hours of birth; the second injection of 10 μg of HBV vaccine will inject at 1 month; and the third dose of 10 μg of HBV vaccine will give at 6 months). The pregnant women and their infants will be followed until postpartum month 7. The primary outcomes are the birth defects and rates of perinatal transmission of HBV. During the prenatal period or the postnatal period up to 7 months of age, cases of a structural defect in newborns or infants were reported as birth defects. The rate of perinatal transmission was defined as the proportion of infants who are positive for hepatitis B surface antigen at 7 months of age. The secondary safety outcomes are the occurrence of maternal or infant adverse events during the study period. Maternal safety evaluations mainly include any adverse events and complications, hepatitis B virologic breakthrough, alanine aminotransferase flare, and so on. Infant' safety profiles mainly included Apgar scores at 1 minute, any abnormal conditions during the study period, and anthropometric indexes at birth and 7 months of age. The secondary efficacy outcomes are the percentages of mothers with an HBV DNA level of less than 200,000 IU per milliliter just before or at delivery, and the hepatitis B e antigen and surface antigen loss or seroconversion in mothers at postpartum month 7.

• Study Type: Interventional
• Enrollment (Anticipated): 240
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Qing-Lei Zeng, M.D.; Phone Number: 86 15838120512; Email: zengqinglei2009@163.com
• Study Contact Backup: Name: Zu-Jiang Yu, M.D.; Phone Number: 86 186 0371 0022; Email: johnyuem@zzu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 40 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Gestational age of more than 30 weeks;
2. Had chronic hepatitis B virus (HBV) infection;
3. HBV DNA > 200,000 IU/ml;
4. Consecutively normal levels of alanine aminotransferase (< 40 U/L) and total bilirubin (< 17.1 μmol/L);
5. Willing and able to provide written informed consent and adhere to the trial protocol.

Exclusion Criteria:

1. Previous treatment to reduce alanine aminotransferase and total bilirubin levels;
2. Previous antiviral treatment for HBV infection (except when antiviral agents were administered for the prevention of perinatal transmission during a previous pregnancy and discontinued more than 6 months before the current pregnancy);
3. Coinfection with hepatitis C, D, E, or human immunodeficiency virus;
4. Previous or current evidence of hepatocellular carcinoma, cirrhosis, systemic or other organ disorders;
5. A hemoglobin level of less than 80 g/L;
6. A neutrophil count of less than 1.0 × 10^9/L;
7. An albumin level of less than 30 g/L;
8. Clinical signs of threatened miscarriage;
9. Evidence of fetal deformity by ultrasound examination and other tests;
10. A history of abortion, pregnancy loss, or congenital malformation in a previous pregnancy;
11. A history of genetic disease(s), including the family member(s);
12. Concurrent treatment with other drugs, including but not limited to nephrotoxic drugs, immune modulators, cytotoxic drugs, nonsteroidal antiinflammatory drugs, or steroids.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Arm 1; Tenofovir alafenamide fumarate discontinued at delivery date.	Drug: Tenofovir Alafenamide fumarate 25mg Oral Tablet; Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.; Other Names: VEMLIDY®
EXPERIMENTAL: Arm 2; Tenofovir alafenamide fumarate discontinued at postpartum month 1.	Drug: Tenofovir Alafenamide fumarate 25mg Oral Tablet; Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.; Other Names: VEMLIDY®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Birth defects.	Structural defect in newborns or infants were reported as birth defects. The monitoring of birth defects was conducted by a clinical examination during each visit, and further clinical imaging or other tests were performed if indicated. The birth defect rate represented the proportion of infants with a defect among all live births.	From prenatal tenofovir alafenamide exposure to the birth and postnatal period up to 7 months of age.
The rate of perinatal transmission of hepatitis B virus.	The rate of perinatal transmission was defined as the proportion of infants who are positive for hepatitis B surface antigen at 7 months of age.	At 7 months of age.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events.	The occurrence of any maternal or infant adverse events.	From prenatal tenofovir alafenamide exposure to the delivery (birth) and postnatal period up to 7 months (of age).
Alanine aminotransferase flare.	Alanine aminotransferase flare was defined as a level greater than 5 or 10 times the upper limit of normal, which was set as 40 U/L according to the Asian-Pacific chronic hepatitis B guideline.	At postpartum month 7.
Infants' growth.	Infant growth was measured by the WHO z scores for age for weight, height, and head circumference.	At birth and 7 months of age.
HBV DNA level.	Percentage of HBV DNA level of less than 200,000 IU per milliliter for mothers.	Immediately before or at delivery.
Hepatitis B e antigen status.	Percentage of hepatitis B e antigen loss or seroconversion for mothers.	At postpartum month 7.
Hepatitis B surface antigen status.	Percentage of hepatitis B surface antigen loss or seroconversion for mothers.	At postpartum month 7.

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital of Zhengzhou University
• Collaborators: National Natural Science Foundation of China; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Shandong Provincial Hospital; Henan Provincial People's Hospital; Second Affiliated Hospital of Xi'an Jiaotong University; Luoyang Central Hospital; Nanyang Central Hospital; Xinyang Central Hospital; Yan'an University Affiliated Hospital; The Sixth People's Hospital of Zhengzhou; First Affiliated Hospital of Nanyang Medical College; Sixth People's Hospital of Kaifeng; Luohe Central Hospital; Fifth People's Hospital of Anyang
• Investigators: Principal Investigator: Qing-Lei Zeng, The First Affiliated hospital of Zhengzhou University

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): April 26, 2021
• Primary Completion (ANTICIPATED): December 31, 2022
• Study Completion (ANTICIPATED): December 31, 2022

Study Registration Dates

• First Submitted: April 9, 2021
• First Submitted That Met QC Criteria: April 14, 2021
• First Posted (ACTUAL): April 20, 2021

Study Record Updates

• Last Update Posted (ACTUAL): April 23, 2021
• Last Update Submitted That Met QC Criteria: April 21, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis B; Hepatitis; Hepatitis A; Hepatitis B, Chronic; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Tenofovir
• Other Study ID Numbers: 2021-KY-0144-002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No